ATI22-107
ATI22-107 is a dual-pharmacophore compound designed to simultaneously inhibit cardiac phosphodiesterase (PDE-III) and L-type calcium channels (LTCC), with activity that has specific effects on calcium cycling and contractility in cat ventricular myocytes and trabeculae.
Product Specifications
CAS Number
681816-57-9
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/ati22-107.html
Smiles
O=C(C1=C(COCCNC(COC2=CC=C(C(CC3)=NNC3=O)C=C2Cl)=O)NC(C)=C(C(OC)=O)C1C4=CC=CC=C4Cl)OC
Molecular Formula
C31H32Cl2N4O8
Molecular Weight
659.51
References & Citations
[1]Pharmacological effects of ATI22-107 [2- (2-{2-[2-chloro-4- (6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl) -phenoxy]-acetylamino}-ethoxymethyl) -4- (2-chloro-phenyl) -6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester) ], a novel dual pharmacophore, on myocyte calcium cycling and contractility
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
